Everything below concerns Phase 3 trial. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
=== Pituitary === Pituitary prolactin is controlled by the Pit-1 transcription factor, which binds to the gene at several sites including a proximal promoter. This promoter is inhibited by dopamine and stimulated by estrogens, neuropeptides, and growth factors. Estrogens can also suppress dopamine. Interaction with neuropeptides is still a matter of active research: no specific prolactin-releasing hormone has been identified. It is known that mice react to both VIP and TRH, but humans seem to only react to TRH. There are prolactin-releasing peptides that work in vitro, but whether they deserve their name has been questioned. Oxytocin does not play a large role. Mice without a posterior pituitary do not raise their prolactin levels even with suckling and oxytocin injection, but scientists have yet to identify which specific hormone produced by this region is responsible. In birds (turkeys), VIP is a powerful prolactin-releasing factor, while peptide histidine isoleucine has almost no effect.
crossing the blood-brain barrier (BBB) in brain diseases and disorders; enhancing targeted intracellular delivery to ensure the treatments reach the correct structures inside cells; combining diagnosis and treatment. The development of new drug systems is time-consuming; it takes approximately seven years to complete fundamental research and development before advancing to preclinical animal studies.
Most assembler designs keep the "source code" external to the physical assembler. At each step of a manufacturing process, that step is read from an ordinary computer file and "broadcast" to all the assemblers. If any assembler gets out of range of that computer, or when the link between that computer and the assemblers is broken, or when that computer is unplugged, the assemblers stop replicating. Such a "broadcast architecture" is one of the safety features recommended by the "Foresight Guidelines on Molecular Nanotechnology", and a map of the 137-dimensional replicator design space recently published by Freitas and Merkle provides numerous practical methods by which replicators can be safely controlled by good design.
Greater than 10%: difficulty sleeping, anxiety, nervousness, abdominal pain/cramps, nausea and/or vomiting, low energy, joint/muscle pain, and headache. Less than 10%: loss of appetite, diarrhea, constipation, thirstiness, increased energy, feeling down, irritability, dizziness, skin rash, delayed ejaculation, erectile dysfunction, and chills. A variety of other adverse events have also been reported with less than 1% incidence.
Sources: en.wikipedia.org
== Sources == Kahn, Charles H. (2001). Pythagoras and the Pythagoreans: A Brief History. Indianapolis, Indiana and Cambridge, England: Hackett Publishing Company. ISBN 978-0-87220-575-8. OCLC 46394974 – via Internet Archive. Varasdi, J. Allen (1996). Myth Information. New York: Ballantine Books. ISBN 0-345-41049-1.
Nausea, vomiting, and diarrhea Dizziness Pulmonary hypertension Coronary artery vasoconstriction Severe systemic hypertension (especially in patients with pre-eclampsia) Convulsions In excessive doses, methylergometrine can also lead to cramping, respiratory depression and coma.
== Lobbying == The company engages in lobbying in the United States. It also lobbies the Government of Ontario and House of Commons of Canada through Rubicon Strategy, a firm owned by Progressive Conservative Party of Ontario campaign manager Kory Teneycke. Pfizer lobbied various officials in the Government of British Columbia between April and November 2012, including then-premier Christy Clark, future premier John Horgan, future health minister Adrian Dix, and future deputy premier, minister of public safety and solicitor general Mike Farnworth. Notable lobbying organizations or think tanks to which the company has contributed include BIOTECanada, Bipartisan Policy Center, The Business Council, Business Council for the United Nations, Center on Budget and Policy Priorities, European Federation of Pharmaceutical Industries and Associations, Foundation for the National Institutes of Health, Global Health Council, Innovative Medicines Canada, International Federation of Pharmaceutical Manufacturers & Associations, National Health Council, Pharmaceutical Advertising Advisory Board, Pharmaceutical Research and Manufacturers of America, Reagan-Udall Foundation, U.S. Global Leadership Coalition, and World Economic Forum.
Police Reservists and regular police officers organised in a similar way were called the Police Anti Terrorist Unit or PATU. Police of all ranks to chief inspector, were obliged to perform PATU secondment on a regular rotation basis, and deployed to operational areas. Riot standby units were also maintained to deal with urban civil disorder on the same basis. Counter insurgency and advanced weapons training were mandatory by the 1970s in anticipation of PATU and district duties. The BSAP also oversaw the intelligence collection function of the Selous Scouts. That function was performed by an embedded element of the BSAP's Special Branch (SB), commanded by Chief Superintendent Michael "Mac" McGuinness; the SB liaison team conducted interrogations of captured guerrillas, reviewed captured documents, and collated and disseminated intelligence. The SB team also oversaw the production and insertion of poisoned clothing, food, beverages, and medicines into the guerrilla supply chain. The use of contaminated supplies resulted in the reported deaths of over 800 guerrillas, and the likely death toll probably reached well over 1,000.
The president of the Republic of the Union of Myanmar (Burmese: နိုင်ငံတော်သမ္မတ, MLCTS: nuing ngam tau samma.ta., lit. 'President of the State') is the head of state and head of government of Myanmar. The president chairs the National Defence and Security Council and leads the Union Government (Cabinet), the executive branch of the Myanmar government. The presidency was established in 1948, when Burma gained its independence from the British Empire. During this period, the president was the ceremonial head of state while prime minister is the actual head of government. The presidency was abolished following the 1962 coup d'etat, when Ne Win assumed the powers of both head of state and head of government as the Chairman of the Revolutionary Council and the Revolutionary Government. The 1974 Constitution reintroduced the presidency, to be held by the Chairman of the Council of State. The 1988 coup d'etat again led to the presidency's abolishment, with the Chairman of the State Law and Order Restoration Council (reconstituted in 1997 as the State Peace and Development Council) assuming the functions of the head of state. The 2008 Constitution introduced a presidential system, where the president is both the head of state and government. Thein Sein assumed the presidency in 2011. After the 2015 election, the extraconstitutional post of State Counsellor of Myanmar was created for Aung San Suu Kyi, the leader of the majority party, the National League for Democracy, because she was ineligible for the presidency.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.